Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

Biorregulatory therapy significantly improved the dog's health, reversing previous issues and eliminating the need for ongoing medication.

Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.

Transepidermal drug delivery effectively treated areata alopecia with minimal side effects.

Autoimmune diseases need combined therapy of tolerance induction and immunosuppression.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.

Truncated hHb1 keratin may play a role in breast cancer cell transformation.

Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.

Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

Blocking certain immune signals can reduce skin damage from radiation therapy.

Rapamycin increased survival in mice with severe chronic graft-versus-host disease by expanding regulatory T cells.

Transplant patients on immunosuppressive medications have a higher risk of skin cancer, and managing this involves balancing medication with cancer risk.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.

Tamoxifen increases the risk of lasting hair loss after chemotherapy despite scalp cooling.

Chemotherapy adds to, but doesn't enhance, the effects of immunotherapy in lung cancer treatment.

Tumor immunotherapy can cause hair loss by disrupting hair follicle immunity.

Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.

AHCC reduces hair loss and liver injury caused by chemotherapy in rodents.

CAR-T cell therapy shows promise for treating autoimmune disorders but faces challenges like complex manufacturing and limited tissue penetration.

Dupilumab may help regrow hair in people with severe alopecia.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.

Trichoblastomas in rabbits are linked to uncontrolled embryonic hair growth and have distinct histological features.

CAR-T therapy offers hope for children with hard-to-treat blood cancers.